HomeCategory Uncategorized

Stuart Therapeutics Announces Chief Medical and Chief Financial Officer Appointments

STUART, Fla., Feb. 1, 2024 /PRNewswire/ — Stuart Therapeutics, Inc. (“Stuart“), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today announced that it has appointed Jodi Luchs, MD to the position of Chief Medical Officer, and Don Stires to the position of Chief Financial Officer. With the appointment of Dr. Luchs, Robert Baratta, MD has stepped...

Stuart Therapeutics Announces Receipt of Study May Proceed Letter from U.S. FDA for ST-100 Dry Eye Disease Phase 2 Clinical Trial

Stuart Therapeutics Announces Receipt of Study May Proceed Letter from U.S. FDA for ST-100 Dry Eye Disease Phase 2 Clinical Trial Stuart Therapeutics (Stuart) announced today that the U.S. Food and Drug Administration (FDA) has completed its review of an Investigational New Drug (IND) application for Stuart’s investigational product ST-100, a topical drop formulation designed...

Stuart Therapeutics, Inc. Announces Pro-Neuronal Growth Results Using PolyColTM Collagen Mimetic Peptides

STUART, FLORIDA November 11th, 2019: Stuart Therapeutics, Inc. (STUART), an innovative pre-clinical therapeutic development company, today announced that it has successfully completed in vitro pro-neuronal growth experiments utilizing the company’s PolyColTM (PolyCol) peptide. PolyCol demonstrated a strong propensity to encourage neurite outgrowth from dorsal root ganglia nerve cells in a model designed to mirror damage...

Stuart Therapeutics, Inc. Announces a Strategic Partnership with Ora, Inc.

STUART, FLORIDA June 12, 2019: Stuart Therapeutics, Inc. (STUART), an innovative pre-clinical ophthalmic therapeutic development company, today announces it has entered into a strategic partnership with Ora®, Inc. (“ORA”), the premier global ophthalmology contract research organization. ORA is investing in its partnership with STUART by providing CMC program execution, IND preparation, and related strategic consulting...

Stuart Therapeutics Announces Positive Retinal Indication in vitro Results for PolyCol

Stuart Therapeutics, Inc., a pre-clinical stage life sciences company developing solutions for difficult to treat ophthalmic diseases, today announced positive results from in vitro experiments using its proprietary collagen mimetic peptide (CMP), PolyColTM (PolyCol) to probe applicability for conditions associated with dry age-related macular degeneration (Dry AMD). The experimental results demonstrate that PolyCol: Promotes proliferation,...

Stuart Therapeutics Receives Positive Response in Pre-IND Meeting with FDA for its Dry Eye Disease Therapeutic Candidate, ST-100

Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced today that it has successfully completed a pre-IND meeting regarding the development plan for ST-100, Stuart’s first drug candidate for Dry Eye Disease (DED). The meeting, held with the Food and Drug Administration’s Center for Drug Evaluation and Research, Division of Transplant...

Stuart Therapeutics, Inc. Announces Relationship with Ora, Inc. for IND Preparation, Regulatory Advisory, and Clinical Trial Services for ST-100

Stuart Therapeutics, Inc. Announces Relationship with Ora, Inc. for IND Preparation, Regulatory Advisory, and Clinical Trial Services for ST-100 STUART, FLORIDA February 25, 2019: Stuart Therapeutics, Inc. (STUART), an innovative pre-clinical therapeutic development company, today announced that it has retained the services of Ora®, Inc., the premier ophthalmology Contract Research Organization (“CRO”) globally, to provide...

Stuart Therapeutics Announces Corneal Epithelial Healing and Organization Pre-Clinical Results for its Potential Dry Eye Therapeutic

Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced important pre-clinical in vivo proof of concept results for its collagen mimetic polypeptide therapeutic, PolyColTM (PolyCol). The company announced additional important results from its mouse eye wound tests. Previous results showed statistically significant results for both acceleration of epithelial cell growth and...

Stuart Therapeutics Announces Important Pre-Clinical Results for ST-100

Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced important pre-clinical in vivo proof of concept results for its collagen mimetic polypeptide therapeutic, PolyColTM (PolyCol). Mouse eye wound tests conducted at the University of Louisville demonstrated rapid, high quality healing of corneal wounds, results that support Stuart’s development of PolyCol as...

Stuart Therapeutics has been selected as a semi-finalist in the BioPitch competition at the 21st annual BioFlorida Conference

Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced today that it has been selected as a semi-finalist in the BioPitch competition at the 21st annual BioFlorida Conference, October 14th – 16th in Ft. Lauderdale, Florida. The BioPitch competition annually selects 15 companies as semi-finalists that present in front of angel...